Dana-Farber, Phosphoproteomics, and Cell Signaling Technology sign agreement relating to phospho-peptide specific antibody technology
October 23, 2003: The Dana-Farber Cancer Institute (Boston, MA), Phosphoproteomics, LLC (Guilford, CT) and Cell Signaling Technology, Inc. (Beverly, MA), announced today that they have resolved their differences pertaining to certain phospho-peptide specific antibody technology described and claimed in Dana-Farber’s re-examined U.S. Patent No. 5,599,681 (Epstein et al.) and Phosphoproteomics’ U.S. Application No. 08/146,235 (Laudano et al.), and have signed a definitive agreement pertaining to the same. Under the agreement, the terms of which were not disclosed, Cell Signaling Technology has secured freedom-to-operate in the research and diagnostic fields in exchange for certain cash payments to the other parties.
“This settlement strengthens Cell Signaling Technology’s leadership position in providing highest-quality reagents for signal transduction research and diagnostic development,” said Chief Executive Officer Michael J. Comb, Ph.D. “By settling our differences with Dana-Farber and Phosphoproteomics and securing freedom-to-operate in both the research and diagnostic fields, Cell Signaling Technology has distinguished itself even further as the partner-of-choice in development and commercialization of phospho-antibody based assays and diagnostics,” Dr. Comb further stated, “Our settlement also clears the way for an increased level of synergy and collaboration between our company and Dana-Farber, both of which are leaders in elucidating the mechanisms underlying cancer.”